BR0311840A - Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo - Google Patents

Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo

Info

Publication number
BR0311840A
BR0311840A BR0311840-1A BR0311840A BR0311840A BR 0311840 A BR0311840 A BR 0311840A BR 0311840 A BR0311840 A BR 0311840A BR 0311840 A BR0311840 A BR 0311840A
Authority
BR
Brazil
Prior art keywords
group
aryl
optionally substituted
compound
alkyl group
Prior art date
Application number
BR0311840-1A
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0311840A publication Critical patent/BR0311840A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, MéTODO PARA TRATAR OU EVITAR RESISTêNCIA à INSULINA, USO DE UM COMPOSTO, E, PROCESSO PARA PREPARá-LO". Um composto da fórmula (I) em que-- R^ 1^ representa arila opcionalmente substituído com um grupo heterocíclico ou um grupo heterocíclico opcionalmente substituído com arila em que cada arila ou grupo heterocíclico é opcionalmente substituído; o grupo -(CH2~ 2~)~ m~-T(CH~ 2~)~ n~-(CH~ 2~)~ p~é ligado na posição 3 ou 4 no anel de fenila como indicado pelos números na fórmula (I) e representa um grupo selecionado de um ou mais dos seguintes: O(CH~ 2~)~ 2~, O(CH~2~)~ 3~, NC(O)NR^ 4^(CH~ 2~)~ 2~, CH~ 2~S(0~ 2~)NR^ 5^(CH~ 2~)~ 2~, CH~ 2~N(R^ 6^C(O)CH^ 2^, (CH^ 2~N)R^ 6^)C(O)(CH~ 2~)~ 2~, C(O)NR^ 7^CH~ 2~, C(O)NR^ 7^CH~ 2~)~ 2~ e CH~ 2~N(R^ 6^)C(O)CH^ 2~0; V representa 0, S, NR^ 8^ ou uma ligação simples; q representa 1, 2 ou 3; W representa 0, S, N(R^ 9^)C(O), NR^ 10^, ou uma ligação simples; R^ 2^ representa halo, um grupo alquila C~ 1-4~ que é opcionalmente substituído com um ou mais flúor, um grupo alcóxi C~ 1-4~, que é opcionalmente substituído com um ou mais flúor, um grupo acila C~ 1-4~, arila, um grupo aril alquila C~ 1-4~, CN ou NO~ 2~; r representa 0, 1, 2 ou 3; R^ 3^ representa halo, um grupo alquila C~ 1-4~ que é opcionalmente substituído com um ou mais flúor, um grupo alcóxi C~ 1-4~ que é opcionalmente substituído com um ou mais flúor, um grupo acila C~ 1-4~, arila, um grupo aril alquila C~ 1-4~ ou CN; s representa 0, 1, 2 ou 3 e R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^, R^ 9^, e R^ 10^ independentemente representa H, um grupo alquila C110, arila ou um grupo aril alquila C~ 1-4~ ou quando m for O e T representa um grupo N(R^ 6^)C(O) ou um grupo (R^ 5^)NS(0~ 2~) então R^ 1^ e R^ 6^ ou R^ 1^ e R^ 5^ juntos com o átomo de nitrogênio ao qual estão ligados representam um grupo heteroarila; com condições e sais farmaceuticamente aceitáveis destes, processos para a preparação de tais compostos, sua utilidade no tratamento de condições clínicas associadas com a resistência à insulina, métodos para seu uso terapêutico e composições farmacêuticas que os contenham.
BR0311840-1A 2002-06-20 2003-06-17 Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo BR0311840A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
PCT/GB2003/002598 WO2004000295A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma

Publications (1)

Publication Number Publication Date
BR0311840A true BR0311840A (pt) 2005-03-15

Family

ID=20288295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311840-1A BR0311840A (pt) 2002-06-20 2003-06-17 Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo

Country Status (21)

Country Link
US (1) US7521461B2 (pt)
EP (1) EP1517680A1 (pt)
JP (1) JP4327085B2 (pt)
KR (1) KR20050014014A (pt)
CN (1) CN100400512C (pt)
AR (1) AR040332A1 (pt)
AU (1) AU2003240101B2 (pt)
BR (1) BR0311840A (pt)
CA (1) CA2490687A1 (pt)
IL (1) IL165672A0 (pt)
IS (1) IS7639A (pt)
MX (1) MXPA04012694A (pt)
NO (1) NO20045222L (pt)
NZ (1) NZ536972A (pt)
PL (1) PL375078A1 (pt)
RU (1) RU2339613C2 (pt)
SE (1) SE0201937D0 (pt)
TW (1) TW200403209A (pt)
UA (1) UA77527C2 (pt)
WO (1) WO2004000295A1 (pt)
ZA (1) ZA200409690B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
DE60319084T2 (de) * 2002-06-20 2009-01-29 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
CN100482649C (zh) 2003-09-17 2009-04-29 诺瓦提斯公司 有机化合物
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA2594345C (en) 2004-12-28 2013-11-05 Kinex Pharmaceuticals, Llc Compositions and methods of treating cell proliferation disorders
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
JP2007234800A (ja) 2006-02-28 2007-09-13 Tdk Corp 電子部品及びその製造方法
CN101454275B (zh) * 2006-03-31 2014-07-23 得克萨斯大学体系董事会 口服生物可利用的咖啡酸相关的抗癌药
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
ES2438768T3 (es) 2007-04-11 2014-01-20 Omeros Corporation Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN102905700A (zh) 2010-04-16 2013-01-30 金克斯医药品有限公司 用于预防和治疗癌症的组合物以及方法
WO2013019621A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
SI2890680T1 (en) 2012-08-30 2018-08-31 Athenex, Inc. Conventus Building N- (3-FLUOROBENZYL) -2- (5- (4-MORFOLINOPHENYL) PIRIDIN-2-IL) ACETAMIDE AS PROTEIN TIROZINE KINASE PROTECTORS
EP3719010B1 (en) * 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
US20230077316A1 (en) * 2020-10-23 2023-03-09 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DK148576A (da) * 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
US5334753A (en) * 1992-03-12 1994-08-02 Rhone-Poulenc Agriculture Ltd Processes for preparing ortho-substituted benzoic acids
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
DE19616948C1 (de) 1996-04-27 1997-11-27 Wagner Gmbh J Schneidwerkzeug, insbesondere Astschere
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
AU9696198A (en) * 1997-10-17 1999-05-10 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
DE69821985T2 (de) 1997-12-19 2005-05-04 Schering Ag Ortho-anthranilamide derivate als antikoagulantien
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
KR100693771B1 (ko) 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CZ20013833A3 (cs) 1999-04-28 2002-02-13 Aventis Pharma Deutschland Gmbh Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
RU2004135542A (ru) 2005-08-10
RU2339613C2 (ru) 2008-11-27
TW200403209A (en) 2004-03-01
US7521461B2 (en) 2009-04-21
ZA200409690B (en) 2005-10-11
IL165672A0 (en) 2006-01-15
WO2004000295A1 (en) 2003-12-31
CA2490687A1 (en) 2003-12-31
CN1662230A (zh) 2005-08-31
EP1517680A1 (en) 2005-03-30
KR20050014014A (ko) 2005-02-05
AU2003240101B2 (en) 2006-09-21
MXPA04012694A (es) 2005-03-23
NO20045222L (no) 2005-01-19
PL375078A1 (en) 2005-11-14
NZ536972A (en) 2006-06-30
UA77527C2 (en) 2006-12-15
IS7639A (is) 2005-01-12
JP4327085B2 (ja) 2009-09-09
US20050267149A1 (en) 2005-12-01
SE0201937D0 (sv) 2002-06-20
AU2003240101A1 (en) 2004-01-06
JP2006502105A (ja) 2006-01-19
CN100400512C (zh) 2008-07-09
AR040332A1 (es) 2005-03-30

Similar Documents

Publication Publication Date Title
BR0311840A (pt) Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo
BRPI0015203B8 (pt) derivado de quinazolina, composição farmacêutica, e, uso de um composto
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
BR0108456A (pt) Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BR9909666A (pt) Derivados de amida e antagonistas de nociceptina
DE69827785D1 (de) 1,4-substituierte cyclische aminderivate
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
BRPI0412363A (pt) compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases
DK160984C (da) Analogifremgangsmaade til fremstilling af dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK0389282T3 (da) Xanthinderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BR0008753A (pt) Composto de amida, processo para sua preparação e seu uso
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
ATE105556T1 (de) Benzopyranverbindungen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen.
BR0003848A (pt) Compostos de piridina, processo para sua preparação e composições farmacêuticas que os contêm
DE69131359T2 (de) Kondensierte Thiazolverbindungen, ihre Darstellung und ihre Anwendung
HUP0201722A2 (hu) Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére
DK43683A (da) Aromatiske forbindelser med antihistamin-aktivitet, fremgangsmaade til deres fremstilling samt deres anvendelse
ATE276257T1 (de) Pyrazinonderivate
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
BR9903282A (pt) Compostos de nitrona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES.